Anne-Céline Martin1,2, Sarah Lessire3, Isabelle Leblanc4,5, Anne-Sophie Dincq3, Ivan Philip4, Isabelle Gouin-Thibault2,6,7, Anne Godier2,5. 1. Service de Cardiologie, Service de Santé des Armées, Hôpital d'Instruction des Armées Percy, Clamart, France. 2. Faculté de Pharmacie, Inserm UMRS_1140, Université Paris Descartes, Paris, France. 3. Namur Thrombosis and Haemostasis Center, Department of Anesthesiology, Université Catholique de Louvain, Namur, Belgium. 4. Service d'Anesthésie, Institut Mutualiste Montsouris, Paris, France. 5. Service d'Anesthésie-Réanimation, Fondation Adolphe de Rothschild, Paris, France. 6. Laboratoire d'Hématologie, AP-HP, Hôpital Cochin, Paris, France. 7. Laboratoire d'Hématologie, Hôpital Pontchaillou, Rennes, France.
Abstract
BACKGROUND: Guidelines recommend performing atrial fibrillation (AF) catheter ablation without interruption of a direct oral anticoagulants (DOACs) and to administer unfractionated heparin (UFH) for an activated clotting time (ACT) ≥300 seconds, by analogy with vitamin K antagonist (VKA). Nevertheless, pharmacological differences between DOACs and VKA, especially regarding ACT sensitivity and UFH response, prevent extrapolation from VKA to DOACs. HYPOTHESIS: The level of anticoagulation at the time of the procedure in uninterrupted DOAC-treated patients is unpredictable and would complicate intraprocedural UFH administration and monitoring. METHODS: This prospective study included interrupted DOAC-treated patients requiring AF ablation. Preprocedural DOAC concentration ([DOAC]), intraprocedural UFH administration, and ACT values were recorded. A cohort of DOAC-treated patients requiring flutter catheter ablation was considered to illustrate [DOAC] without DOAC interruption. RESULTS: Forty-eight patients underwent AF and 14 patients underwent flutter ablation, respectively. In uninterrupted DOAC-treated patients, [DOAC] ranged from ≤30 to 466 ng/mL. When DOAC were interrupted, from 54 to 218 hours, [DOAC] were minimal (maximum: 36 ng/mL), preventing DOAC-ACT interference. Anyway, ACT values were poorly correlated with UFH doses (R 2 = 0.2256). CONCLUSIONS: Our data showed that uninterrupted DOAC therapy resulted in an unpredictable and highly variable initial level of anticoagulation before catheter ablation. Moreover, even with DOAC interruption preventing interference between DOAC, UFH, and ACT, intraprocedural UFH monitoring was complex. Altogether, our exploratory results call into question the appropriateness of transposing UFH dose protocols, as well as the relevance of ACT monitoring in uninterrupted DOAC-treated patients.
BACKGROUND: Guidelines recommend performing atrial fibrillation (AF) catheter ablation without interruption of a direct oral anticoagulants (DOACs) and to administer unfractionated heparin (UFH) for an activated clotting time (ACT) ≥300 seconds, by analogy with vitamin K antagonist (VKA). Nevertheless, pharmacological differences between DOACs and VKA, especially regarding ACT sensitivity and UFH response, prevent extrapolation from VKA to DOACs. HYPOTHESIS: The level of anticoagulation at the time of the procedure in uninterrupted DOAC-treated patients is unpredictable and would complicate intraprocedural UFH administration and monitoring. METHODS: This prospective study included interrupted DOAC-treated patients requiring AF ablation. Preprocedural DOAC concentration ([DOAC]), intraprocedural UFH administration, and ACT values were recorded. A cohort of DOAC-treated patients requiring flutter catheter ablation was considered to illustrate [DOAC] without DOAC interruption. RESULTS: Forty-eight patients underwent AF and 14 patients underwent flutter ablation, respectively. In uninterrupted DOAC-treated patients, [DOAC] ranged from ≤30 to 466 ng/mL. When DOAC were interrupted, from 54 to 218 hours, [DOAC] were minimal (maximum: 36 ng/mL), preventing DOAC-ACT interference. Anyway, ACT values were poorly correlated with UFH doses (R 2 = 0.2256). CONCLUSIONS: Our data showed that uninterrupted DOAC therapy resulted in an unpredictable and highly variable initial level of anticoagulation before catheter ablation. Moreover, even with DOAC interruption preventing interference between DOAC, UFH, and ACT, intraprocedural UFH monitoring was complex. Altogether, our exploratory results call into question the appropriateness of transposing UFH dose protocols, as well as the relevance of ACT monitoring in uninterrupted DOAC-treated patients.
Authors: L C Brendel; F Dobler; G Hessling; J Michel; S L Braun; A L Steinsiek; P Groha; R Eckl; I Deisenhofer; A Hyseni; M Roest; I Ott; B Steppich Journal: J Interv Card Electrophysiol Date: 2017-07-22 Impact factor: 1.900
Authors: Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas Journal: Eur Heart J Date: 2016-08-27 Impact factor: 29.983
Authors: Sandeep Gautam; Roy M John; William G Stevenson; Rahul Jain; Laurence M Epstein; Usha Tedrow; Bruce A Koplan; Seth McClennen; Gregory F Michaud Journal: J Cardiovasc Electrophysiol Date: 2010-08-31
Authors: Luigi Di Biase; J David Burkhardt; Pasquale Santangeli; Prasant Mohanty; Javier E Sanchez; Rodney Horton; G Joseph Gallinghouse; Sakis Themistoclakis; Antonio Rossillo; Dhanunjaya Lakkireddy; Madhu Reddy; Steven Hao; Richard Hongo; Salwa Beheiry; Jason Zagrodzky; Bai Rong; Sanghamitra Mohanty; Claude S Elayi; Giovanni Forleo; Gemma Pelargonio; Maria Lucia Narducci; Antonio Dello Russo; Michela Casella; Gaetano Fassini; Claudio Tondo; Robert A Schweikert; Andrea Natale Journal: Circulation Date: 2014-04-17 Impact factor: 29.690
Authors: Philippe Maury; Slimane Belaid; Agnès Ribes; Quentin Voglimacci-Stephanopoli; Pierre Mondoly; Marie Blaye; Franck Mandel; Benjamin Monteil; Didier Carrié; Michel Galinier; Vanina Bongard; Anne Rollin; Sophie Voisin Journal: J Arrhythm Date: 2020-05-19